Summary of Study ST001369

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000922. The data can be accessed directly via it's Project DOI: 10.21228/M8HH5M This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples | Perform analysis on untargeted data
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)

Study ID	ST001369
Study Title	Grass pollen sublingual immunotherapy treatment induces transcriptomic and metabolic changes due to AIT treatment
Study Summary	47 patients were enrolled in a double-blind, placebo-controlled, multicenter trial using with GRAZAX® (Phleum pretense) during 2 years of therapy (T2). Immunological assays such as sIgE, sIgG4 and ISAC were carried out to the 31 patients who finished the trial. Additionally, serum and PBMCs samples from these samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were grouped in Mono and Poli groups, excluding epithelial allergic patients. Individuals were studied based on their treatment in Active and Placebo and their sensitization level. For metabolomics, samples were analyzed by Liquid and Gas Chromatography coupled to Mass Spectrometry (LC-MS and GC-MS, respectively).
Institute	Institute of Applied Molecular Medicine;The Centre of Metabolomics and Bioanalysis
Last Name	Obeso Montero
First Name	David
Address	Avda. Monteprincipe s/n 28668 Boadilla del Monte, Madrid, España
Email	david.obesomontero@beca.ceu.es
Phone	Tlf: 91 372 47 00 ext. 4662
Submit Date	2020-03-27
Num Groups	2 main groups: Active and Placebo, and 2 subgroups: Monosensitized and Polisensitized patients.
Total Subjects	22
Study Comments	https://www.ceu.es;http://www.metabolomica.uspceu.es
Raw Data Available	Yes
Raw Data File Type(s)	d
Analysis Type Detail	GC-MS/LC-MS
Release Date	2020-09-29
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001458
Treatment Summary:	Subjects were randomized (1:1) during autumn 2013 to receive either active treatment with GRAZAX® (Phleum pratense, 75,000SQ‐T tablets ALK, Hørsholm, Denmark) or placebo as Investigational Medical Products (IMP) during 2 years. Twenty-five patients were assigned to daily sublingual administration of GRAZAX®, while the rest received placebo tablets that were similar to the active IMP with regard to appearance, smell and taste.

Treatment ID:

TR001458

Treatment Summary:

Subjects were randomized (1:1) during autumn 2013 to receive either active treatment with GRAZAX® (Phleum pratense, 75,000SQ‐T tablets ALK, Hørsholm, Denmark) or placebo as Investigational Medical Products (IMP) during 2 years. Twenty-five patients were assigned to daily sublingual administration of GRAZAX®, while the rest received placebo tablets that were similar to the active IMP with regard to appearance, smell and taste.